1
|
Zirkle J, Han X, Racz R, Samieegohar M, Chaturbedi A, Mann J, Chakravartula S, Li Z. Deep learning-enabled natural language processing to identify directional pharmacokinetic drug-drug interactions. BMC Bioinformatics 2023; 24:413. [PMID: 37914988 PMCID: PMC10619324 DOI: 10.1186/s12859-023-05520-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 10/04/2023] [Indexed: 11/03/2023] Open
Abstract
BACKGROUND During drug development, it is essential to gather information about the change of clinical exposure of a drug (object) due to the pharmacokinetic (PK) drug-drug interactions (DDIs) with another drug (precipitant). While many natural language processing (NLP) methods for DDI have been published, most were designed to evaluate if (and what kind of) DDI relationships exist in the text, without identifying the direction of DDI (object vs. precipitant drug). Here we present a method for the automatic identification of the directionality of a PK DDI from literature or drug labels. METHODS We reannotated the Text Analysis Conference (TAC) DDI track 2019 corpus for identifying the direction of a PK DDI and evaluated the performance of a fine-tuned BioBERT model on this task by following the training and validation steps prespecified by TAC. RESULTS This initial attempt showed the model achieved an F-score of 0.82 in identifying sentences as containing PK DDI and an F-score of 0.97 in identifying object versus precipitant drugs in those sentences. DISCUSSION AND CONCLUSION Despite a growing list of NLP methods for DDI extraction, most of them use a common set of corpora to perform general purpose tasks (e.g., classifying a sentence into one of several fixed DDI categories). There is a lack of coordination between the drug development and biomedical informatics method development community to develop corpora and methods to perform specific tasks (e.g., extract clinical exposure changes due to PK DDI). We hope that our effort can encourage such a coordination so that more "fit for purpose" NLP methods could be developed and used to facilitate the drug development process.
Collapse
Affiliation(s)
- Joel Zirkle
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
| | - Xiaomei Han
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
| | - Rebecca Racz
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
| | - Mohammadreza Samieegohar
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
| | - Anik Chaturbedi
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
| | - John Mann
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
| | - Shilpa Chakravartula
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
| | - Zhihua Li
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.
| |
Collapse
|
2
|
Zhan D, Young DS. Finite mixtures of mean-parameterized Conway-Maxwell-Poisson models. Stat Pap (Berl) 2023:1-24. [PMID: 37360788 PMCID: PMC10197059 DOI: 10.1007/s00362-023-01452-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 05/02/2023] [Indexed: 06/28/2023]
Abstract
For modeling count data, the Conway-Maxwell-Poisson (CMP) distribution is a popular generalization of the Poisson distribution due to its ability to characterize data over- or under-dispersion. While the classic parameterization of the CMP has been well-studied, its main drawback is that it is does not directly model the mean of the counts. This is mitigated by using a mean-parameterized version of the CMP distribution. In this work, we are concerned with the setting where count data may be comprised of subpopulations, each possibly having varying degrees of data dispersion. Thus, we propose a finite mixture of mean-parameterized CMP distributions. An EM algorithm is constructed to perform maximum likelihood estimation of the model, while bootstrapping is employed to obtain estimated standard errors. A simulation study is used to demonstrate the flexibility of the proposed mixture model relative to mixtures of Poissons and mixtures of negative binomials. An analysis of dog mortality data is presented. Supplementary Information The online version contains supplementary material available at 10.1007/s00362-023-01452-x.
Collapse
Affiliation(s)
- Dongying Zhan
- Dr. Bing Zhang Department of Statistics, University of Kentucky, 725 Rose Street, Lexington, KY 40536-0082 USA
| | - Derek S. Young
- Dr. Bing Zhang Department of Statistics, University of Kentucky, 725 Rose Street, Lexington, KY 40536-0082 USA
| |
Collapse
|
3
|
MSEDDI: Multi-Scale Embedding for Predicting Drug-Drug Interaction Events. Int J Mol Sci 2023; 24:ijms24054500. [PMID: 36901929 PMCID: PMC10002564 DOI: 10.3390/ijms24054500] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 02/18/2023] [Accepted: 02/22/2023] [Indexed: 03/02/2023] Open
Abstract
A norm in modern medicine is to prescribe polypharmacy to treat disease. The core concern with the co-administration of drugs is that it may produce adverse drug-drug interaction (DDI), which can cause unexpected bodily injury. Therefore, it is essential to identify potential DDI. Most existing methods in silico only judge whether two drugs interact, ignoring the importance of interaction events to study the mechanism implied in combination drugs. In this work, we propose a deep learning framework named MSEDDI that comprehensively considers multi-scale embedding representations of the drug for predicting drug-drug interaction events. In MSEDDI, we design three-channel networks to process biomedical network-based knowledge graph embedding, SMILES sequence-based notation embedding, and molecular graph-based chemical structure embedding, respectively. Finally, we fuse three heterogeneous features from channel outputs through a self-attention mechanism and feed them to the linear layer predictor. In the experimental section, we evaluate the performance of all methods on two different prediction tasks on two datasets. The results show that MSEDDI outperforms other state-of-the-art baselines. Moreover, we also reveal the stable performance of our model in a broader sample set via case studies.
Collapse
|
4
|
Pan D, Quan L, Jin Z, Chen T, Wang X, Xie J, Wu T, Lyu Q. Multisource Attention-Mechanism-Based Encoder-Decoder Model for Predicting Drug-Drug Interaction Events. J Chem Inf Model 2022; 62:6258-6270. [PMID: 36449561 DOI: 10.1021/acs.jcim.2c01112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
Many computational methods have been proposed to predict drug-drug interactions (DDIs), which can occur when combining drugs to treat various diseases, but most mainly utilize single-source features of drugs, which is inadequate for drug representation. To fill this gap, we propose two attention-mechanism-based encoder-decoder models that incorporate multisource information: one is MAEDDI, which can predict DDIs, and the other is MAEDDIE, which can make further DDI-associated event predictions for drug pairs with DDIs. To better express the drug feature, we used three encoding methods to encode the drugs, integrating the self-attention mechanism, cross-attention mechanism, and graph attention network to construct a multisource feature fusion network. Experiments showed that both MAEDDI and MAEDDIE performed better than some state-of-the-art methods in various validation attempts at different experimental tasks. The visualization analysis showed that the semantic features of drug pairs learned from our models had a good drug representation. In practice, MAEDDIE successfully screened 43 DDI events on favipiravir, an influenza antiviral drug, with a success rate of nearly 50%. Our model achieved competitive results, mainly owing to the design of sequence-based, structural, biochemical, and statistical multisource features. Moreover, different encoders constructed based on different features learn the interrelationship information between drug pairs, and the different representations of these drug pairs are incorporated to predict the target problem. All of these encoders were designed to better characterize the complex DDI relationships, allowing us to achieve high generalization in DDI and DDI-associated event predations.
Collapse
Affiliation(s)
- Deng Pan
- School of Computer Science and Technology, Soochow University, Suzhou215006, China
| | - Lijun Quan
- School of Computer Science and Technology, Soochow University, Suzhou215006, China.,Province Key Lab for Information Processing Technologies, Soochow University, Suzhou215006, China.,Collaborative Innovation Center of Novel Software Technology and Industrialization, Nanjing210000, China
| | - Zhi Jin
- School of Computer Science and Technology, Soochow University, Suzhou215006, China
| | - Taoning Chen
- School of Computer Science and Technology, Soochow University, Suzhou215006, China
| | - Xuejiao Wang
- School of Computer Science and Technology, Soochow University, Suzhou215006, China
| | - Jingxin Xie
- School of Computer Science and Technology, Soochow University, Suzhou215006, China
| | - Tingfang Wu
- School of Computer Science and Technology, Soochow University, Suzhou215006, China.,Province Key Lab for Information Processing Technologies, Soochow University, Suzhou215006, China.,Collaborative Innovation Center of Novel Software Technology and Industrialization, Nanjing210000, China
| | - Qiang Lyu
- School of Computer Science and Technology, Soochow University, Suzhou215006, China.,Province Key Lab for Information Processing Technologies, Soochow University, Suzhou215006, China.,Collaborative Innovation Center of Novel Software Technology and Industrialization, Nanjing210000, China
| |
Collapse
|
5
|
Qiu Y, Zhang Y, Deng Y, Liu S, Zhang W. A Comprehensive Review of Computational Methods For Drug-Drug Interaction Detection. IEEE/ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS 2022; 19:1968-1985. [PMID: 34003753 DOI: 10.1109/tcbb.2021.3081268] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The detection of drug-drug interactions (DDIs) is a crucial task for drug safety surveillance, which provides effective and safe co-prescriptions of multiple drugs. Since laboratory researches are often complicated, costly and time-consuming, it's urgent to develop computational approaches to detect drug-drug interactions. In this paper, we conduct a comprehensive review of state-of-the-art computational methods falling into three categories: literature-based extraction methods, machine learning-based prediction methods and pharmacovigilance-based data mining methods. Literature-based extraction methods detect DDIs from published literature using natural language processing techniques; machine learning-based prediction methods build prediction models based on the known DDIs in databases and predict novel ones; pharmacovigilance-based data mining methods usually apply statistical techniques on various electronic data to detect drug-drug interaction signals. We first present the taxonomy of drug-drug interaction detection methods and provide the outlines of three categories of methods. Afterwards, we respectively introduce research backgrounds and data sources of three categories, and illustrate their representative approaches as well as evaluation metrics. Finally, we discuss the current challenges of existing methods and highlight potential opportunities for future directions.
Collapse
|
6
|
Meng L, Huang J, Qiu F, Shan X, Chen L, Sun S, Wang Y, Yang J. Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. Front Pharmacol 2022; 13:757415. [PMID: 35359859 PMCID: PMC8963930 DOI: 10.3389/fphar.2022.757415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2021] [Accepted: 02/15/2022] [Indexed: 11/13/2022] Open
Abstract
Backgrounds: Proteasome inhibitors (PI) cause toxic peripheral neuropathy (PN), which is one of the dose-limiting adverse events of these treatments. Recent preclinical studies find that factor Xa inhibitor (FXaI), rivaroxaban, promotes PN in animals receiving oxaliplatin. Cancer patients can receive combined therapy of PI and FXaI. This study aimed to identify and characterize the interaction signals for the concomitant use of PI and FXaI resulting in PN.Methods: Reports from the United States FDA Adverse Event Reporting System (FAERS) were extracted from the first quarter of 2004 to the first quarter of 2020 for analysis. The Standardized Medical Dictionary for Regulatory Activities (MedDRA) query was used to identify PN cases. We conducted an initial disproportionality investigation to detect PN adverse event signals associated with the combined use of PI and FXaI by estimating a reporting odds ratio (ROR) with a 95% confidence interval (CI). The adjusted RORs were then analyzed by logistic regression analysis (adjusting for age, gender, and reporting year), and additive/multiplicative models were performed to further confirm the findings. Additionally, subset data analysis was performed on the basis of a single drug of PI and FXaI.Results: A total of 159,317 adverse event reports (including 2,822 PN reports) were included. The combined use of PI and FXaI was associated with a higher reporting of PN (RORadj = 7.890, 95%CI, 5.321–11.698). The result remained significant based on additive/multiplicative methods. The observed association was consistent in the analysis restricted to all specific PI agents (bortezomib and ixazomib) and FXaI (rivaroxaban), except apixaban.Conclusion: Analysis of FAERS data identified reporting associations of PN in the combined use of PI and FXaI, suggesting the need for more robust preclinical and clinical studies to elucidate the relationship.
Collapse
Affiliation(s)
- Long Meng
- Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University, Chongqing, China
- Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Jing Huang
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Feng Qiu
- Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xuefeng Shan
- Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Lin Chen
- Department of Pharmacy, Chongqing Health Center for Women and Children, Chongqing, China
| | - Shusen Sun
- Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA, United States
- Department of Pharmacy, Xiangya Hospital Central South University, Changsha, China
| | - Yuwei Wang
- Chongqing University Cancer Hospital, Chongqing, China
| | - Junqing Yang
- Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University, Chongqing, China
- *Correspondence: Junqing Yang,
| |
Collapse
|
7
|
Shin H, Kim N, Cha J, Kim GJ, Kim JH, Kim JY, Lee S. Geriatrics on beers criteria medications at risk of adverse drug events using real-world data. Int J Med Inform 2021; 154:104542. [PMID: 34411951 DOI: 10.1016/j.ijmedinf.2021.104542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 05/31/2021] [Accepted: 06/17/2021] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The established Beers Criteria consider side effects and safety concerns when prescribing drugs to the elderly. As the criteria suggest that attention should be paid toward prescriptions rather than prescription prohibition lists, these Beers Criteria medications (BCMs) are used appropriately under unavoidable circumstances. METHODS Patients aged ≥ 65 years and with an experience of being prescribed inappropriate medications at Konyang University Hospital, South Korea, were selected. We analyzed data from the Korea Adverse Event Reporting System (KAERS) and the Food and Drug Administration Adverse Event Reporting System (FAERS) of the United States to identify medication-induced adverse drug events (ADEs). The actual incidence was predicted by multiplying the incidence and number of BCMs prescribed to the patients. The proportional reporting ratio (PRR) and reporting odds ratio (ROR) were calculated using KAERS and FAERS data. RESULTS We predicted that the incidence of ADEs would be higher for metoclopramide, chlorpheniramine, and amitriptyline in patients using medications for more than 1 day and metoclopramide, chlorpheniramine, and ketoprofen in patients using medications only for 1 day. Among the ADEs reported to KAERS and FAERS, significant ROR and PRR values were noted for clonazepam (drowsiness), nortriptyline (sleepiness), and zolpidem (amnesia, somnambulism, agitation, dependence, nightmare, and dysgeusia). CONCLUSION This study highlighted the actual status of BCM prescriptions in clinical institutions and predicted the incidence of ADEs. We concluded that greater care must be taken while prescribing BCMs to the elderly and indicators, such as PRR and ROR should be monitored regularly.
Collapse
Affiliation(s)
- Hyunah Shin
- Health Care Data Science Center, Konyang University Hospital, Daejeon, Republic of Korea
| | - Nanyeong Kim
- Departments of Biomedical Informatics, Konyang University College of Medicine, Daejeon, Republic of Korea
| | - Jaehun Cha
- Health Care Data Science Center, Konyang University Hospital, Daejeon, Republic of Korea
| | - Grace Juyun Kim
- Seoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Ju Han Kim
- Seoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Jong-Yeup Kim
- Health Care Data Science Center, Konyang University Hospital, Daejeon, Republic of Korea; Departments of Biomedical Informatics, Konyang University College of Medicine, Daejeon, Republic of Korea
| | - Suehyun Lee
- Health Care Data Science Center, Konyang University Hospital, Daejeon, Republic of Korea; Departments of Biomedical Informatics, Konyang University College of Medicine, Daejeon, Republic of Korea.
| |
Collapse
|
8
|
The 2011–2020 Trends of Data-Driven Approaches in Medical Informatics for Active Pharmacovigilance. APPLIED SCIENCES-BASEL 2021. [DOI: 10.3390/app11052249] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Pharmacovigilance, the scientific discipline pertaining to drug safety, has been studied extensively and is progressing continuously. In this field, medical informatics techniques and interpretation play important roles, and appropriate approaches are required. In this study, we investigated and analyzed the trends of pharmacovigilance systems, especially the data collection, detection, assessment, and monitoring processes. We used PubMed to collect papers on pharmacovigilance published over the past 10 years, and analyzed a total of 40 significant papers to determine the characteristics of the databases and data analysis methods used to identify drug safety indicators. Through systematic reviews, we identified the difficulty of standardizing data and terminology and establishing an adverse drug reactions (ADR) evaluation system in pharmacovigilance, and their corresponding implications. We found that appropriate methods and guidelines for active pharmacovigilance using medical big data are still required and should continue to be developed.
Collapse
|
9
|
Correia RB, Wood IB, Bollen J, Rocha LM. Mining Social Media Data for Biomedical Signals and Health-Related Behavior. Annu Rev Biomed Data Sci 2020; 3:433-458. [PMID: 32550337 PMCID: PMC7299233 DOI: 10.1146/annurev-biodatasci-030320-040844] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Social media data have been increasingly used to study biomedical and health-related phenomena. From cohort-level discussions of a condition to population-level analyses of sentiment, social media have provided scientists with unprecedented amounts of data to study human behavior associated with a variety of health conditions and medical treatments. Here we review recent work in mining social media for biomedical, epidemiological, and social phenomena information relevant to the multilevel complexity of human health. We pay particular attention to topics where social media data analysis has shown the most progress, including pharmacovigilance and sentiment analysis, especially for mental health. We also discuss a variety of innovative uses of social media data for health-related applications as well as important limitations of social media data access and use.
Collapse
Affiliation(s)
- Rion Brattig Correia
- Instituto Gulbenkian de Cincia, 2780-156 Oeiras, Portugal
- Center for Social and Biomedical Complexity, Luddy School of Informatics, Computing & Engineering, Indiana University, Bloomington, Indiana 47408, USA
- CAPES Foundation, Ministry of Education of Brazil, 70040 Braslia DF, Brazil
| | - Ian B Wood
- Center for Social and Biomedical Complexity, Luddy School of Informatics, Computing & Engineering, Indiana University, Bloomington, Indiana 47408, USA
| | - Johan Bollen
- Center for Social and Biomedical Complexity, Luddy School of Informatics, Computing & Engineering, Indiana University, Bloomington, Indiana 47408, USA
| | - Luis M Rocha
- Instituto Gulbenkian de Cincia, 2780-156 Oeiras, Portugal
- Center for Social and Biomedical Complexity, Luddy School of Informatics, Computing & Engineering, Indiana University, Bloomington, Indiana 47408, USA
| |
Collapse
|
10
|
Hauser AS, Kooistra AJ, Sverrisdóttir E, Sessa M. Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance. Expert Opin Drug Saf 2020; 19:961-968. [PMID: 32510245 DOI: 10.1080/14740338.2020.1780208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
INTRODUCTION Signal detection is the most pivotal activity of signal management to guarantee that drugs maintain a positive risk-benefit ratio during their lifetime on the market. Signal detection is based on the systematic evaluation of available data sources, which have recently been extended in order to improve timely and comprehensive signal detection of drug safety problems. AREAS COVERED In recent years, attempts have been made to incorporate pharmacological data for the prediction of safety signals. Previous studies have shown that data on the pharmacological targets of drugs are predictive of post-marketing adverse events. However, current approaches limit such predictions to adverse events expected from the interaction of a drug with the main pharmacological target and do not take off-target interactions into consideration. EXPERT OPINION The authors propose the application of predictive modeling techniques utilizing pharmacological data from public databases for predicting drug-target-event relationships deriving from main- and off-target binding and from which potential safety signals can be deduced. Additionally, they provide an operative procedure for the identification of clinically relevant subgroups for predicted safety signals.
Collapse
Affiliation(s)
| | - Albert Jelke Kooistra
- Department of Drug Design and Pharmacology, University of Copenhagen , Copenhagen, Denmark
| | - Eva Sverrisdóttir
- Department of Drug Design and Pharmacology, University of Copenhagen , Copenhagen, Denmark
| | - Maurizio Sessa
- Department of Drug Design and Pharmacology, University of Copenhagen , Copenhagen, Denmark
| |
Collapse
|
11
|
Yao X, Tsang T, Sun Q, Quinney S, Zhang P, Ning X, Li L, Shen L. Mining and visualizing high-order directional drug interaction effects using the FAERS database. BMC Med Inform Decis Mak 2020; 20:50. [PMID: 32183790 PMCID: PMC7079342 DOI: 10.1186/s12911-020-1053-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background Adverse drug events (ADEs) often occur as a result of drug-drug interactions (DDIs). The use of data mining for detecting effects of drug combinations on ADE has attracted growing attention and interest, however, most studies focused on analyzing pairwise DDIs. Recent efforts have been made to explore the directional relationships among high-dimensional drug combinations and have shown effectiveness on prediction of ADE risk. However, the existing approaches become inefficient from both computational and illustrative perspectives when considering more than three drugs. Methods We proposed an efficient approach to estimate the directional effects of high-order DDIs through frequent itemset mining, and further developed a novel visualization method to organize and present the high-order directional DDI effects involving more than three drugs in an interactive, concise and comprehensive manner. We demonstrated its performance by mining the directional DDIs associated with myopathy using a publicly available FAERS dataset. Results Directional effects of DDIs involving up to seven drugs were reported. Our analysis confirmed previously reported myopathy associated DDIs including interactions between fusidic acid with simvastatin and atorvastatin. Furthermore, we uncovered a number of novel DDIs leading to increased risk for myopathy, such as the co-administration of zoledronate with different types of drugs including antibiotics (ciprofloxacin, levofloxacin) and analgesics (acetaminophen, fentanyl, gabapentin, oxycodone). Finally, we visualized directional DDI findings via the proposed tool, which allows one to interactively select any drug combination as the baseline and zoom in/out to obtain both detailed and overall picture of interested drugs. Conclusions We developed a more efficient data mining strategy to identify high-order directional DDIs, and designed a scalable tool to visualize high-order DDI findings. The proposed method and tool have the potential to contribute to the drug interaction research and ultimately impact patient health care. Availability and implementation http://lishenlab.com/d3i/explorer.html
Collapse
Affiliation(s)
- Xiaohui Yao
- Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Tiffany Tsang
- Department of Computer and Information Science, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Qing Sun
- Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Sara Quinney
- Department of Obstetrics and Gynecology, School of Medicine, Indiana University, Indianapolis, IN, 46202, USA
| | - Pengyue Zhang
- Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, 43210, USA
| | - Xia Ning
- Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, 43210, USA
| | - Lang Li
- Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, 43210, USA
| | - Li Shen
- Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
| |
Collapse
|
12
|
Quinney SK. Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk. Clin Pharmacol Ther 2019; 106:72-74. [PMID: 31184772 PMCID: PMC6617974 DOI: 10.1002/cpt.1481] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Accepted: 04/17/2019] [Indexed: 12/22/2022]
Affiliation(s)
- Sara K Quinney
- Department of Obstetrics and Gynecology and Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, School of Informatics and Computing, Indiana University Purdue University Indianapolis, Indianapolis, Indiana, USA
| |
Collapse
|
13
|
Li L. Reverse Translational Pharmacology Research Is Driven by Big Data. CPT Pharmacometrics Syst Pharmacol 2018; 7:63-64. [PMID: 29457706 PMCID: PMC5824108 DOI: 10.1002/psp4.12277] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Accepted: 01/04/2018] [Indexed: 02/03/2023] Open
Affiliation(s)
- Lang Li
- Department of Biomedical InformaticsCollege of Medicine, The Ohio State UniversityColumbusOhioUSA
| |
Collapse
|